Sunday, December 16, 2012
Poll: Top Nephrology-Related Stories of 2012
Subscribe to:
Post Comments (Atom)
NSMC Founding Member
Partner
A nice repository of landmark articles and reviews in the field of nephrology at UKidney. Visual Abstracts are also included.
Partner
Endorsed by
NephJC
The Online Nephrology Journal Club
The Glomerular Disease Study & Trial Consortium (GlomCon)
Endorsed Educational Resource
Subscribe to the Concepts in Hypertension Newsletter
Top 7 posts from RFN (data from page views in the last 7 days)
-
Neph Sim (click to access the tool) is a mobile-friendly nephrology teaching tool designed for medical students, residents, and fellows ... -
Hector Madariaga pointed out that Nate blogged about a long forgotten poster from ASN Renal Week 2009. Long before it was even called Kidn... -
Nephro360 (click for a video) is a tool designed to teach the pre-clinical nephrology curriculum and improve student engagement and learni... -
For any 2nd year renal fellows out there reading this: your first chance to take the ABIM Nephrology Boards is coming up this November 18, ... -
This month's eJournal club concerns a paper published by a fellow from our institution that attempts to get to the bottom of an inter...
-
Although the traditional dogma of kidney transplant would state that ABO incompatibility is an absolute contraindication for a kidney transp... -
Eculizumab is a humanized monoclonal antibody (mAb) that binds the complement protein C5 blocking its cleavage into C5a and C5b, thereby p...
Certification
This site complies with the HONcode standard for trustworthy health information:
verify here.
3 comments:
Added another contender... The FDA Innovation Pathway 2.0, a more streamlined and efficient FDA approval process which chose three devices focused on solving problems in the care of patients with ESRD.
Darn, looks like we can't edit the poll now that it's opened. Comment here if you want vote for the FDA Innovation Pathway 2.0 :)
The only story that should get any votes is Temp 3:4. Major break through which, unless turns out to be a type 1 error, will rank with ACEi and EPO as standout pharmaceutical moments in nephrology. The tolvaptan story will be on your list of stories of the decade in December 2019, unless you've graduated by then.
Post a Comment